Therapy Directory

Pomalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention. Browse Pomalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

204

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Dexamethasone, Filgrastim-sndz, Laboratory Biomarker Analysis, Pomalidomide; Drug · Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab SAR650984, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 13
States / cities: Scottsdale, Arizona • Duarte, California • New Haven, Connecticut + 9 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 22
States / cities: Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more

Conditions: Multiple Myeloma
Interventions: Venetoclax, Pomalidomide, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Columbus, Georgia • Fairway, Kansas • St Louis, Missouri + 2 more

Conditions: Recurrent Plasma Cell Myeloma
Interventions: Dexamethasone, HDAC Inhibitor AR-42, Laboratory Biomarker Analysis, Pomalidomide; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Myeloma
Interventions: Oprozomib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 17
States / cities: Encinitas, California • West Hollywood, California • Whittier, California + 13 more

Conditions: Multiple Myeloma
Interventions: Pomalidomide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Multiple Myeloma
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more

Conditions: Chronic Lymphocytic Leukemia, B-Cell Lymphoma
Interventions: DTRMWXHS-12, DTRM-505, DTRM-555; Drug
Lead sponsor: Zhejiang DTRM Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 3 more

Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia-2, High Risk Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions: Cytarabine, Daunorubicin Hydrochloride, Etoposide, Idarubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: New Haven, Connecticut • Baltimore, Maryland • Chapel Hill, North Carolina

Conditions: AL Amyloidosis
Interventions: Pomalidomide, Dexamethasone; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia
Interventions: Pomalidomide; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

About this Pomalidomide clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pomalidomide.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Pomalidomide clinical trials

Filter and sort this therapy

Live official records

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis

Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study

About this Pomalidomide clinical trials directory page